Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
New cancer gene therapy study results from University of Turku described
February 17th, 2009
"The relative paucity of receptors for the commonly used adenovirus serotype 5 in many cancer types undermines the efficacy of Ad5-based approach for cancer gene therapy. We have previously shown that coxsackie-adenovirus receptor (CAR) is expressed at decreased levels in several primary head and neck squamous cell carcinoma (HNSCC) cell lines established from tumor samples and that retargeting adenoviral infection to the CD46 receptor using the Ad5/35 hybrid virus results in highly efficient transfection of these cells," scientists in Turku, Finland report. "We sought to examine the effect of this retargeting in the context of the conditionally replicating adenovirus...
Source: Cancer Weekly (2009-02-17)
|
